Mangoceuticals, Inc. (NASDAQ: MGRX), operating as MangoRx, is a Dallas-based telemedicine company specializing in men’s health and wellness. The company offers treatments for conditions such as erectile dysfunction, hair loss, and hormone imbalances through a secure online platform, enabling consumers to consult with licensed physicians and receive medications discreetly at their doorstep.
On March 25, 2025, Mangoceuticals announced it has entered into a Master Distribution Agreement to secure the exclusive licensing and distribution rights for Diabetinol® within the United States and Canada. Diabetinol® is a clinically supported and patented plant-based nutraceutical derived from citrus peel, rich in polymethoxylated flavones (PMFs) like nobiletin and tangeretin. Clinical studies have demonstrated that these compounds significantly impact metabolic processes, particularly in how the body processes and utilizes sugar and fat. Mechanistically, Diabetinol® works by improving insulin sensitivity, enhancing GLUT4-mediated glucose uptake in tissues, suppressing hepatic glucose production, and activating key enzymes involved in lipid metabolism. It also reduces systemic inflammation and oxidative stress—two primary biological drivers of insulin resistance and metabolic dysfunction. This strategic move positions Mangoceuticals to expand its product portfolio into the $33.66 billion addressable diabetes and metabolic health market.
Following the announcement, Mangoceuticals’ stock experienced a significant decline, closing at $2.81 on March 25, 2025, down approximately 41.68% from the previous close. Despite this drop, the company’s 52-week range has seen highs of $16.80, indicating potential volatility. The recent dip may present a buying opportunity for investors who believe in the company’s strategic direction and its expansion into the metabolic health sector.
Jacob Cohen, Founder and CEO of Mangoceuticals, commented on the expansion:
“Millions of people are left on the sidelines watching others lose weight using drugs they can’t afford. Diabetinol® is not a direct substitute for those prescription therapies, but the internal studies have concluded that it does offer complementary metabolic benefits in a safe, natural, and more affordable way. By harnessing clinically proven plant-derived ingredients, we’re providing a new option for individuals who cannot access or tolerate GLP-1 medications. Our goal is to help more people take control of their blood sugar and weight – safely, conveniently, and cost-effectively.”
Mangoceuticals plans to distribute Diabetinol® in multiple consumer-friendly formats, including capsules, ready-to-drink beverages, quick-release pouches, cookies, and gummies. Distribution channels are expected to encompass direct-to-consumer online initiatives via the company’s website and through online retailers, brick-and-mortar retail outlets, and affiliate marketing channels.
This expansion aligns with Mangoceuticals’ mission to improve lives through safe and accessible wellness solutions, addressing the escalating diabetes crisis and the growing demand for affordable metabolic health products.
Marc has been involved in the Stock Market Media Industry for the last +5 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website.
